{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:55:46Z","timestamp":1792418146561,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017556","name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.modpat.2023.100165","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:26:39Z","timestamp":1679916399000},"page":"100165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9965-288X","authenticated-orcid":false,"given":"Israel S.","family":"Kasago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid K.","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"Lezcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Febres-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Vanderbilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snjezana","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus J.","family":"Busam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-243X","authenticated-orcid":false,"given":"Meera","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.modpat.2023.100165_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2559.2000.00894.x","article-title":"Morphological and immunophenotypic variations in malignant melanoma","volume":"36","author":"Banerjee","year":"2000","journal-title":"Histopathology"},{"issue":"Suppl 2","key":"10.1016\/j.modpat.2023.100165_bib2","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1038\/modpathol.3800516","article-title":"Unusual variants of malignant melanoma","volume":"19","author":"Magro","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100165_bib3","article-title":"Primary esophageal melanoma with aberrant CD56 expression: a potential diagnostic pitfall","volume":"2017","author":"Katerji","year":"2017","journal-title":"Case Rep Pathol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100165_bib4","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/s41379-021-00857-z","article-title":"The clinicopathologic spectrum and genomic landscape of de-\/trans-differentiated melanoma","volume":"34","author":"Ferreira","year":"2021","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PAS.0000000000000527","article-title":"Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated\/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker","volume":"40","author":"Agaimy","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100165_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102060","article-title":"Dedifferentiated melanomas: morpho-phenotypic profile, genetic reprogramming and clinical implications","volume":"88","author":"Massi","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/PAS.0000000000001645","article-title":"Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria","volume":"45","author":"Agaimy","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.modpat.2023.100165_bib8","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1038\/modpathol.2013.174","article-title":"An approach to pleomorphic sarcomas: can we subclassify, and does it matter?","volume":"27","author":"Goldblum","year":"2014","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100165_bib9","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1245\/s10434-015-4453-z","article-title":"Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions","volume":"22","author":"Dineen","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.modpat.2023.100165_bib10","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1038\/sj.onc.1206450","article-title":"Ultraviolet radiation and cutaneous malignant melanoma","volume":"22","author":"Jhappan","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/phpp.12329","article-title":"Mechanisms and prevention of UV-induced melanoma","volume":"34","author":"Sample","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"10.1016\/j.modpat.2023.100165_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jso.20972","article-title":"Diagnosis and management of pleomorphic sarcomas (so-called \u201cMFH\u201d) in adults","volume":"97","author":"Nascimento","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100165_bib13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ans.15348","article-title":"Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases","volume":"89","author":"Vodanovich","year":"2019","journal-title":"ANZ J Surg"},{"issue":"11","key":"10.1016\/j.modpat.2023.100165_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.modpat.2023.100165_bib15","doi-asserted-by":"crossref","first-page":"TPS11587","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS11587","article-title":"PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies","volume":"36","author":"Toulmonde","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100165_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100165_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7463","key":"10.1016\/j.modpat.2023.100165_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"7793","key":"10.1016\/j.modpat.2023.100165_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"6312","key":"10.1016\/j.modpat.2023.100165_bib21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"issue":"1-2","key":"10.1016\/j.modpat.2023.100165_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mrfmmm.2004.06.057","article-title":"Mutations induced by ultraviolet light","volume":"571","author":"Pfeifer","year":"2005","journal-title":"Mutat Res"},{"issue":"1-2","key":"10.1016\/j.modpat.2023.100165_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mrfmmm.2004.09.012","article-title":"Ultraviolet radiation-mediated damage to cellular DNA","volume":"571","author":"Cadet","year":"2005","journal-title":"Mutat Res"},{"issue":"6","key":"10.1016\/j.modpat.2023.100165_bib24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.modpat.2023.100165_bib25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrg3579","article-title":"Cancer genomics: signature analysis suggests cancer origins","volume":"14","author":"Lokody","year":"2013","journal-title":"Nat Rev Genet"},{"issue":"11","key":"10.1016\/j.modpat.2023.100165_bib26","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/s41379-020-0594-0","article-title":"Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma","volume":"33","author":"Yang","year":"2020","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100165_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"issue":"D1","key":"10.1016\/j.modpat.2023.100165_bib29","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.modpat.2023.100165_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jmoldx.2020.02.009","article-title":"Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes","volume":"22","author":"Kroeze","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12885-019-5677-2","article-title":"Portrait of a cancer: mutational signature analyses for cancer diagnostics","volume":"19","author":"Van Hoeck","year":"2019","journal-title":"BMC Cancer"},{"issue":"7420","key":"10.1016\/j.modpat.2023.100165_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.modpat.2023.100165_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","article-title":"Immunotherapy resistance by inflammation-induced dedifferentiation","volume":"8","author":"Mehta","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13256-017-1238-y","article-title":"The undifferentiated carcinoma that became a melanoma: re-biopsy of a cancer of an unknown primary site: a case report","volume":"11","author":"R\u00f8e","year":"2017","journal-title":"J\u00a0Med Case Rep"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13569-020-00133-9","article-title":"Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report","volume":"10","author":"Arora","year":"2020","journal-title":"Clin Sarcoma Res"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jso.26306","article-title":"The emerging role of immunotherapy for the treatment of sarcoma","volume":"123","author":"Klemen","year":"2021","journal-title":"J\u00a0Surg Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100165_bib37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0000000000000675","article-title":"Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors","volume":"40","author":"Agaram","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100165_bib40","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.modpat.2023.100165_bib41","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-20-4189","article-title":"Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas","volume":"27","author":"Shoushtari","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib42","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib43","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib44","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","article-title":"Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours","volume":"11","author":"Johansson","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.modpat.2023.100165_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41379-018-0175-7","article-title":"Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma","volume":"32","author":"Zhu","year":"2019","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100165_bib46","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A\u00a0landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cam4.4472","article-title":"Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med"},{"issue":"7399","key":"10.1016\/j.modpat.2023.100165_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Berger","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.modpat.2023.100165_bib52","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/0008-5472.CAN-15-1722","article-title":"Notch4 signaling induces a mesenchymal\u2013epithelial\u2013like transition in melanoma cells to suppress malignant behaviors","volume":"76","author":"Bonyadi Rad","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2023.100165_bib53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fonc.2013.00333","article-title":"Evidence that GRIN2A mutations in melanoma correlate with decreased survival","volume":"3","author":"D\u2019mello","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2023.100165_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-62703-727-3_24","article-title":"ERBB4 mutation analysis: emerging molecular target for melanoma treatment","volume":"1102","author":"Lau","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.modpat.2023.100165_bib55","article-title":"De novo mutation in non-tyrosine kinase domain of ROS1 as a potential predictor of immune checkpoint inhibitors in melanoma","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100165_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J\u00a0Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100165_bib57","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1440-1827.2010.02570.x","article-title":"Diagnostic utility of EWS break-apart fluorescence in situ hybridization in distinguishing between non-cutaneous melanoma and clear cell sarcoma","volume":"60","author":"Song","year":"2010","journal-title":"Pathol Int"},{"issue":"8","key":"10.1016\/j.modpat.2023.100165_bib58","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/1878-0261.12748","article-title":"Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy","volume":"14","author":"Pham","year":"2020","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00000658-199301000-00012","article-title":"Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients","volume":"217","author":"Fong","year":"1993","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.modpat.2023.100165_bib60","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1245\/s10434-022-11803-x","article-title":"Sentinel lymph node biopsy and formal lymphadenectomy for soft tissue sarcoma: a single center experience of 86 consecutive cases","volume":"29","author":"Witt","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"4 Pt. 2","key":"10.1016\/j.modpat.2023.100165_bib61","first-page":"1751","article-title":"Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications","volume":"176","author":"Godbole","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100165_bib62","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/modpathol.2008.86","article-title":"Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall","volume":"21","author":"Bahrami","year":"2008","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2353\/ajpath.2009.080631","article-title":"Molecular classification of rhabdomyosarcoma\u2014genotypic and phenotypic determinants of diagnosis: a report from the Children\u2019s Oncology Group","volume":"174","author":"Davicioni","year":"2009","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100165_bib64","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.2002.03.137","article-title":"PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"20","author":"Sorensen","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/PAS.0000000000000538","article-title":"A\u00a0molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases","volume":"40","author":"Alaggio","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"16","key":"10.1016\/j.modpat.2023.100165_bib66","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2015.134","article-title":"Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics","volume":"29","author":"Schaefer","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100165_bib68","author":"Creager"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/modpathol.2014.109","article-title":"Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas","volume":"28","author":"Pekmezci","year":"2015","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/dvdy.24226","article-title":"Tumors of the neural crest: common themes in development and cancer","volume":"244","author":"Maguire","year":"2015","journal-title":"Dev Dyn"},{"issue":"12","key":"10.1016\/j.modpat.2023.100165_bib71","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/00000478-199912000-00007","article-title":"Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor: report of 16 cases","volume":"23","author":"King","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-15-1090","article-title":"A\u00a0preclinical model of malignant peripheral nerve sheath tumor-like melanoma is characterized by infiltrating mast cells","volume":"76","author":"H\u00f6lzel","year":"2016","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.modpat.2023.100165_bib73","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/modpathol.2017.91","article-title":"Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions","volume":"30","author":"Le Guellec","year":"2017","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100165_bib74","first-page":"1379","article-title":"Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma","volume":"25","author":"Wu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib75","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab Invest"},{"issue":"5","key":"10.1016\/j.modpat.2023.100165_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/his.12305","article-title":"BRAF mutation in \u201csarcomas\u201d: a possible method to detect de-differentiated melanomas","volume":"64","author":"Cipriani","year":"2014","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib77","first-page":"245","article-title":"Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients","volume":"30","author":"Jin","year":"2010","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40291-015-0133-8","article-title":"Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay","volume":"19","author":"Greco","year":"2015","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00325","article-title":"Therapeutic implication of genomic landscape of adult metastatic sarcoma","volume":"3","author":"Feng","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100165_bib80","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/modpathol.2013.168","article-title":"TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas","volume":"27","author":"Griewank","year":"2014","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100165_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.modpat.2023.100165_bib82","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11864-017-0489-6","article-title":"Conception and management of a poorly understood spectrum of dermatologic neoplasms: atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma","volume":"18","author":"Soleymani","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100165_bib83","first-page":"2345","article-title":"Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures","volume":"9","author":"Cheung","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12105-019-01084-4","article-title":"Soft tissue special issue: cutaneous pleomorphic spindle cell tumors","volume":"14","author":"Brenn","year":"2020","journal-title":"Head Neck Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib85","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/modpathol.2017.146","article-title":"Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1\/2 and FAT1 mutations and similar DNA copy number alteration profiles","volume":"31","author":"Griewank","year":"2018","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100165_bib86","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41379-020-0530-3","article-title":"BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma","volume":"33","author":"Watanabe","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100165_bib87","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.6004\/jnccn.2013.0173","article-title":"Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor","volume":"11","author":"Kaplan","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-020-0928-8","article-title":"An NRAS mutation in primary malignant melanoma of the lung: a case report","volume":"15","author":"Hibiya","year":"2020","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PAI.0000000000000500","article-title":"SP174 antibody lacks specificity for NRAS Q61R and cross-reacts with HRAS and KRAS Q61R mutant proteins in malignant melanoma","volume":"26","author":"Felisiak-Gol\u0105bek","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100165_bib90","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/PAI.0000000000000333","article-title":"NRASQ61R mutation-specific immunohistochemistry is highly specific for either NRASQ61R or KRASQ61R mutation in colorectal carcinoma","volume":"25","author":"Turchini","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100165_bib91","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/PAS.0000000000001673","article-title":"The diagnostic utility of RAS Q61R mutation-specific immunohistochemistry in epithelial-myoepithelial carcinoma","volume":"45","author":"Nakaguro","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100165_bib92","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"M\u00fcller","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.modpat.2023.100165_bib93","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.modpat.2023.100165_bib94","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41379-018-0161-0","article-title":"Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma","volume":"32","author":"Alrabadi","year":"2019","journal-title":"Mod Pathol"},{"issue":"34","key":"10.1016\/j.modpat.2023.100165_bib95","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.18632\/oncotarget.27701","article-title":"A\u00a0case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy","volume":"11","author":"Torresetti","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.modpat.2023.100165_bib96","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.adro.2019.07.019","article-title":"Use of immunotherapy and radiation treatment in the management of metastatic melanoma with rhabdomyosarcomatous differentiation","volume":"5","author":"Gupta","year":"2020","journal-title":"Adv Radiat Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:23:21Z","timestamp":1760232201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0893395223000704"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100165","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100165"}}